{
    "title": "Merck sees 2022 sales up nearly 20%, mostly on molnupiravir",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10472343/Merck-sees-2022-sales-nearly-20--molnupiravir.html",
    "date": "2022-02-03",
    "keywords": [
        "share",
        "year",
        "drug",
        "pill",
        "merck",
        "molnupiravir",
        "quarter",
        "litchfield",
        "supply",
        "business",
        "erman",
        "covid19",
        "company",
        "trial",
        "development",
        "co",
        "thursday",
        "percent",
        "drugmaker",
        "partner",
        "ridgeback",
        "officer",
        "caroline",
        "interview",
        "aggregate",
        "treatment",
        "end",
        "weve",
        "product",
        "antiviral",
        "game",
        "changer",
        "efficacy",
        "pfizer",
        "inc",
        "term",
        "average",
        "growth",
        "cancer",
        "keytruda",
        "papillomavirus",
        "hpv",
        "vaccine",
        "gardasil",
        "shy",
        "analyst",
        "revenue",
        "cash",
        "windfall",
        "goal",
        "level",
        "reporting",
        "richard",
        "pullin"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}